Vivani Medical

VANIPhase 1

Vivani Medical aims to revolutionize chronic disease treatment by eliminating adherence challenges through its miniaturized, subdermal drug implants. The company's NanoPortal™ technology has been validated in a successful Phase 1 trial (LIBERATE-1) and is now being applied to a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. With a veteran leadership team and a public listing on NASDAQ, Vivani is positioned to advance its long-acting implant solutions through clinical development.

Market Cap

$94.2M

Focus

Drug Delivery

AI Company Overview

Technology Platform

NanoPortal™ implant technology: a miniature, subdermal drug delivery system engineered to provide steady-state drug release over 6-12 months, addressing medication non-adherence through guaranteed dosing.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
Semaglutide (Wegovy) weekly injection	Obesity & Overweight	Phase 1
Bydureon BCise (exenatide extended release) + Semaglutide, 1.0 mg/mL	Overweight and Obesity	Phase 1

Funding History

Total raised: $45M

IPO$25MUndisclosedJan 28, 2022

Series A$20MUndisclosedJun 15, 2019

Opportunities

Vivani has significant growth opportunities in the massive obesity and type 2 diabetes markets by addressing medication non-adherence with long-acting implants.

The company could expand its platform to other chronic conditions requiring sustained drug delivery and potentially partner with large pharma companies seeking to extend their injectable franchises.

Risk Factors

Key risks include clinical trial failures, regulatory challenges for drug-device combinations, intense competition from large pharma GLP-1 products, adoption hurdles for implantable devices, and ongoing need for capital raising in a pre-revenue stage.

Competitive Landscape

Vivani competes against Novo Nordisk and Eli Lilly's injectable GLP-1 agonists, with differentiation through 6-12 month dosing versus weekly injections. In long-acting delivery, it faces competition from companies like Intarcia, but its miniaturized NanoPortal technology and proven Phase 1 feasibility provide competitive advantages.